Comprehensive medication guide to Tyenne including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$100 per administration or refill for commercially insured patients who also use the KabiCare Copay Program; Tyenne is on the specialty tier (Tier 4–5) for most commercial plans but is a preferred tocilizumab biosimilar on major formularies including BCBS of Michigan and Moda Health as of 2025–2026.
Estimated Cash Pricing
Cash price for the IV formulation starts at approximately $390 for an 80 mg/4 mL vial, but full treatment courses (which may require higher doses) cost significantly more. The SC formulation is similarly priced as a specialty biologic. Most patients access Tyenne through insurance rather than paying cash price.
Medfinder Findability Score
70/100
Summarize with AI
On this page
Tyenne (tocilizumab-aazg) is an FDA-approved biologic medication and a biosimilar to Actemra (tocilizumab), manufactured by Fresenius Kabi USA, LLC. It was first approved by the FDA on March 5, 2024, making it the first tocilizumab biosimilar in the United States to be approved in both intravenous (IV) and subcutaneous (SC) formulations.
Tyenne belongs to the interleukin-6 (IL-6) receptor antagonist class of drugs — a type of targeted biologic therapy that works by blocking a specific protein involved in driving inflammation. It is approved for several inflammatory and autoimmune conditions including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis (PJIA), systemic juvenile idiopathic arthritis (SJIA), cytokine release syndrome (CRS), and COVID-19.
As a biosimilar, Tyenne has been shown to have no clinically meaningful differences in safety, purity, or potency compared to the reference product Actemra. The IV formulation launched on April 15, 2024, and the SC formulation launched on July 2, 2024.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Tyenne is an interleukin-6 (IL-6) receptor antagonist. IL-6 is a cytokine — a protein that acts as a chemical messenger in the immune system, signaling cells to activate inflammation. In conditions like rheumatoid arthritis, IL-6 is overproduced, driving chronic, damaging inflammation in joints and other tissues.
Tyenne works by binding to the IL-6 receptor on cells, physically blocking IL-6 from attaching. When IL-6 cannot bind to its receptor, the inflammatory signal is interrupted — reducing joint swelling, pain, and tissue damage. Tyenne is a recombinant humanized anti-human IL-6 receptor monoclonal antibody.
This same mechanism also explains Tyenne's effectiveness in cytokine release syndrome and severe COVID-19, where runaway IL-6 production drives life-threatening immune overreaction. By blocking IL-6, Tyenne helps calm the immune storm and reduce organ damage.
80 mg/4 mL — IV infusion vial (20 mg/mL)
Single-dose vial for intravenous infusion; clinic-administered
200 mg/10 mL — IV infusion vial (20 mg/mL)
Single-dose vial for intravenous infusion; clinic-administered
400 mg/20 mL — IV infusion vial (20 mg/mL)
Single-dose vial for intravenous infusion; clinic-administered
162 mg/0.9 mL — SC prefilled syringe
Single-dose subcutaneous injection for home self-administration
162 mg/0.9 mL — SC autoinjector (pen)
Single-dose subcutaneous autoinjector for home self-administration
As of 2026, there is no active FDA shortage of Tyenne — the drug has been commercially available through specialty pharmacy channels since its April 2024 launch. However, Tyenne is a specialty biologic, which means it is not stocked at standard retail pharmacies. The SC formulation is dispensed through specialty pharmacies (Walgreens Specialty, CVS Specialty, Accredo, Optum Specialty), while the IV formulation is administered in clinical settings.
The primary access barriers for Tyenne patients are prior authorization (PA) requirements and specialty pharmacy logistics rather than supply shortages. Most insurance plans require PA before approving Tyenne, which can add 2–4 weeks to treatment initiation. Tyenne is now the preferred tocilizumab biosimilar on several major payer formularies, which has improved access compared to prior years.
If you're having trouble locating Tyenne at a pharmacy near you, medfinder can help. medfinder contacts specialty pharmacies near you to check which ones can fill your Tyenne prescription, so you don't have to spend hours on hold.
Tyenne is not a controlled substance and requires no special DEA registration to prescribe. However, due to the complexity of biologic therapy management, required baseline screenings, and ongoing monitoring requirements, Tyenne is most commonly prescribed by specialists with expertise in the conditions it treats.
Rheumatologists: Primary prescribers for RA, GCA, PJIA, and SJIA in adults
Pediatric rheumatologists: For children with PJIA and SJIA (age 2 and older)
Oncologists and hematologists: For cytokine release syndrome following CAR T-cell therapy
Hospitalists and critical care physicians: For the COVID-19 indication in the hospital setting
Nurse practitioners and physician assistants: In a rheumatology specialty practice, NPs and PAs can prescribe Tyenne in most states
Telehealth rheumatology services are growing and can be used for monitoring established patients on Tyenne. Initial prescribing typically requires an in-person evaluation, including a physical exam and baseline laboratory testing (TB screening, CBC, liver function tests, lipid panel) before initiating therapy.
No. Tyenne (tocilizumab-aazg) is not a controlled substance and has no DEA scheduling. It is a specialty prescription biologic that requires a valid prescription and insurance prior authorization, but it is not subject to the refill restrictions, quantity limits, or special prescriber registration requirements that apply to controlled substances.
While Tyenne does not require DEA registration to prescribe, it does require prescribers to complete appropriate monitoring (baseline TB screening, labs) and is typically managed by specialists such as rheumatologists due to its complexity and monitoring requirements.
The most frequently reported side effects in clinical trials include:
Upper respiratory tract infections (colds, sore throat, nasal congestion)
Nasopharyngitis (runny nose and nasal inflammation)
Headache
Hypertension (high blood pressure)
Elevated liver enzymes (ALT/AST)
Injection site reactions — redness, swelling, bruising (SC formulation only)
Serious infections (Boxed Warning): Including TB, bacterial, invasive fungal, viral, and opportunistic infections. Potentially fatal.
Gastrointestinal perforation: Primarily in patients with diverticulitis. Seek emergency care for sudden severe abdominal pain.
Hepatotoxicity: Serious liver injury including cases requiring transplant or death. Report jaundice, dark urine, or severe fatigue immediately.
Neutropenia and thrombocytopenia: Low white blood cell and platelet counts requiring regular monitoring.
Hyperlipidemia: Increased cholesterol, LDL, and triglycerides observed in treated patients.
Anaphylaxis and hypersensitivity: Rare but potentially life-threatening severe allergic reactions.
Know what you need? Skip the search.
Actemra (tocilizumab)
Reference biologic; same IL-6 receptor antagonist mechanism; additionally approved for SSc-ILD not covered by Tyenne
Kevzara (sarilumab)
Another IL-6 receptor antagonist approved for RA in adults; SC only; 200 mg or 150 mg every 2 weeks
Tofidence (tocilizumab-bavi)
First FDA-approved tocilizumab biosimilar; IV formulation only; made by Biogen/Bio-Thera
Avtozma (tocilizumab-anoh)
Third tocilizumab biosimilar; IV and SC; FDA approved January 2025 by Celltrion
Prefer Tyenne? We can find it.
Oral contraceptives
moderateTyenne may increase CYP3A4 metabolism of hormonal contraceptives, potentially reducing their effectiveness. Discuss backup contraception with your doctor.
Statins (lovastatin, atorvastatin, simvastatin)
moderateCYP3A4 substrates; Tyenne may increase statin metabolism, reducing blood levels. Monitor lipids closely as Tyenne itself can raise cholesterol.
TNF inhibitors (Humira, Enbrel, Remicade, etc.)
majorDo not combine with Tyenne. Combining biologics creates excessive immunosuppression and dramatically increases infection risk.
Live vaccines
majorAbsolutely contraindicated. Do not administer live vaccines (MMR, varicella, nasal flu, yellow fever) while on Tyenne.
Methotrexate
moderateCan be used with Tyenne (approved combination for RA) but increases risk of hepatotoxicity. Monitor LFTs closely.
Warfarin
moderateNarrow therapeutic window anticoagulant; Tyenne may alter warfarin metabolism. Increase INR monitoring when starting or stopping Tyenne.
Tyenne (tocilizumab-aazg) represents an important advance in access to IL-6 receptor antagonist therapy. As the first Actemra biosimilar approved for both IV and SC administration, it gives patients and providers more flexibility in how tocilizumab is delivered — while potentially lowering costs compared to the reference product, Actemra.
Commercially insured patients have access to the KabiCare Copay Program, which can reduce out-of-pocket costs to as little as $0. For uninsured patients, the Fresenius Kabi Patient Assistance Program may provide Tyenne at low or no cost. Prior authorization is required by most payers but the process can be streamlined with complete documentation and KabiCare hub enrollment.
If you're having trouble finding Tyenne at a pharmacy near you, medfinder can do the searching for you — contacting specialty pharmacies in your area and texting you results so you can get your prescription filled as quickly as possible.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini